Financial DNA — Every Pattern That Matters

Revenue has grown 5.2× in eight years — from ₹402 Cr in FY17 to ₹2,089 Cr TTM. The deceleration from 33% in FY20 to 11% TTM reflects a maturing LatAm base, not structural deterioration. Two fresh USFDA ANDA approvals in early 2026 (Desmopressin and Sodium Phosphates, combined ~$93M US market) signal the next acceleration phase is beginning. Revenue mix is also derisking: LatAm's 81% share is expected to fall to 60–65% by FY30 as US and Africa scale — a re-rating catalyst in itself.

The FY21 dip to 13% EPS growth is the only meaningful interruption in the decade — and it occurred during peak injectable capex, not competitive pressure. By FY23 EPS growth had bounced back to 25%. The 10yr PEG ratio at current prices: 0.63×. Below 1.0 on a 29% CAGR compounder is historically rare.

*Gross margin estimated from company disclosures and industry benchmarks for backward-integrated generic exporters. The gross-to-operating gap of roughly 24–26pp reflects lean fixed overhead: R&D at ~4.5% of revenue, negligible consumer marketing (B2B institutional sales in LatAm require no advertising), and a vertically integrated manufacturing base that removes outsourcing premiums.

The FY20–22 margin compression is the most important data point in this table — not because margins fell, but because they only fell to 30–31%. Caplin was running a ₹600–650 Cr injectable facility construction programme funded entirely from operating cash. Most companies see OPM dip to 18–22% under that kind of investment load. Caplin's floor was 30%. The recovery to 35% TTM — without any change in the LatAm business — is purely the injectable plant moving from cost drag to revenue contributor.

ROCE above 25% through a ₹650 Cr capex cycle is diagnostic. It means the underlying LatAm business was generating returns so high that the idle capital drag of a half-built injectable plant didn't pull the blended ROCE below the 25% threshold. The floor tells you more than the ceiling.

For context: most Indian pharma exporters run ROCE of 12–18%. Branded domestic pharma companies — with superior pricing power — hover around 20–22%. Caplin achieves 25%+ as a branded generic exporter in semi-regulated markets where competition is real. That is not a lucky outcome. It is the output of 30 years of compounding distribution relationships, regulatory licences, and vertical integration that cannot be replicated quickly.

Most discussions of ROIC in pharma get complicated by debt structures, off-balance-sheet liabilities, and goodwill from acquisitions. Caplin has none of these. The business has grown organically for 30 years, funded entirely by its own cash generation. No equity dilution since inception. No meaningful debt at any point in its history. Every rupee of capital employed is productive operating capital — nothing is financial engineering.

The ROIC calculation is therefore unusually clean: PAT / (Equity + Debt) ≈ PAT / Equity = ROE. At FY25 PAT of ₹541 Cr on equity of roughly ₹3,170 Cr, ROIC runs at approximately 17–20% — which understates the true return on incremental invested capital, because the denominator includes ₹900 Cr+ of accumulated cash that earns only treasury returns. Strip out the cash pile from invested capital, and ROIC on deployed operating capital is materially higher.

The accumulating cash surplus is simultaneously evidence of high ROIC (the business generates more cash than it can intelligently deploy at current scale) and a future ROIC tailwind — as US injectable revenue ramps on infrastructure already built and expensed, incremental ROIC on that segment should be very high.

The clearest single proof of operating leverage: OPM went from 21% in FY14 to 35% TTM while revenue grew 12×. That 14-percentage-point OPM expansion on a 12× revenue base is the mathematical signature of fixed costs compounding over decades. Fixed overhead grew far slower than revenue. Every year, a higher fraction of sales dropped to the operating profit line — automatically, without management intervention.

The FCF story has three chapters. FY14–19: High FCF conversion as the LatAm business matures and cash builds with zero debt. FY20–22: FCF compressed but positive through the ₹650 Cr injectable facility build — the critical point being that it was funded entirely from operating cash, without a rights issue, QIP, or bank line. This is the single most important FCF data point: the investment cycle didn't require a rupee of outside capital. FY23–present: Capex cycle complete, cash generation accelerating, other income growing from ₹55 Cr to ₹113 Cr TTM as the cash pile compounds.

Interest paid is ₹1 Cr on ₹622 Cr of PAT. That 0.16% interest-to-PAT ratio defines what it means to be a clean balance sheet. No debt service drag. No lender covenants. No refinancing risk. The ₹1,540 Cr liquid surplus disclosed by management in June 2023 — and growing since — is dry powder for US development, oncology groundwork, and Africa expansion, without ever touching external capital markets. That self-funding capacity is itself a compounding moat.